Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ecopipam - Emalex Biosciences

Next Previous
Drug Profile

Ecopipam - Emalex Biosciences

Alternative Names: EBS-101; Ecopipam HCl; Ecopipam Hydrochloride; PSYRX 101; SCH-39166

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Schering-Plough
  • Developer Emalex Biosciences; Psyadon Pharmaceuticals; Schering-Plough
  • Class Alcohols; Antipsychotics; Behavioural disorder therapies; Benzazepines; Cardiovascular therapies; Chlorinated hydrocarbons; Drug withdrawal therapies; Heterocyclic compounds with 4 or more rings; Naphthalenes; Obesity therapies; Small molecules
  • Mechanism of Action Dopamine D1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lesch-Nyhan syndrome; Gilles de la Tourette's syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Gilles de la Tourette's syndrome; Lesch-Nyhan syndrome
  • Phase II Speech disorders
  • Phase I/II Restless legs syndrome
  • Phase I Cardiovascular disorders
  • No development reported Gambling
  • Discontinued Cocaine-related disorders; Obesity; Schizophrenia

Most Recent Events

  • 28 May 2025 No recent reports of development identified for phase-I development in Speech disorders(In volunteers) in USA (PO, Tablet)
  • 14 Feb 2025 Emalex Biosciences completes the phase III D1AMOND trial in Gilles de la Tourette's syndrome (In adolescents, In children, In the elderly, In adults) in Bulgaria, Canada, Denmark, France, Germany, Hungary, Italy, Poland, Romania, Serbia, Spain, USA (NCT05615220)
  • 27 Dec 2024 Emalex Biosciences completes a phase I pharmacokinetics trial (In volunteers) in USA (NCT06669091)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top